CAUSE OF RELAPSE GASTRIC CANCER PATIENTS AFTER RADICAL TREATMENT

Gastric cancer is one of the most common malignancies and the third most common cause of cancer-related death worldwide. Recent advances in the surgical treatment of gastric cancer are related to the use of extended lymph node dissection (D2), however, tumor characteristics such as tumor size, histological type, degree of differentiation as well as the presence of lymphovascular invasion and lymph node involvement are well known factors that influence long-term treatment outcomes. The purpose of the study was to analyze the survival rates in patients, who received curative treatment for locally advanced gastric cancer, depending on the extent of lymph node dissection, and tumor characteristics. Material and methods. Using the Kaplan-Meier method and analysis of variance, long-term treatment outcomes were analyzed in 662 patients with gastric cancer, who underwent either limited/standard lymph node dissection (D1) or extended lymph node dissection (D2). Results. The overall and 5-year survival rates were found to be significantly higher in patients undergoing a D2 lymph node dissection than in patients who had a D1 dissection, with the median survival time being 32.0 months compared to 46.0 months, respectively. Tumor characteristics, such as, disease stage, regional lymph node metastasis and invasion grade (poorly differentiated tumor) had a greater impact on survival than the extended lymph node dissection. Conclusion. Extended lymph node dissection (D2) should be performed routinely in the curative surgical treatment of gastric carcinoma. The beneficial effect from D2 lymph node dissection was observed in gastric cancer patients with different histological characteristics such as the type, grade and depth of tumor invasion. The standardization of surgical procedures and detection of the tumor at an early stage lowered the operative risk in the treatment of gastric cancer.

stomach cancer, extended lymphadenectomy, survival, tumor histological structure, regional metastasis

1. Ferlay J., Soerjomataram I., Dikshit R., Eser S., Mathers C., Rebelo M., Parkin D.M., Forman D., Bray F. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015 Mar 1; 136 (5): E359 86. doi: 10.1002/ijc.29210.

2. Kaprin A.D., Starinsky V.V., Petrova G.V. Malignancies in Russia in 2014. Moscow, 2016; 250 p. [in Russian]

3. Kaprin A.D., Starinsky V.V., Petrova. State of cancer care in Russia in 2012. Мoscow, 2013; 232 p. [in Russian]

4. Huang C.M., Lin J.X., Zheng C.H., Li P., Xie J.W., Lin B.J., Lu H.S. Prognostic impact of dissected lymph node count on patients with node-negative gastric cancer. World J Gastroenterol. 2009 Aug 21; 15 (31): 3926–30.

5. Hundahl S.A., Wanebo H.J. Changing gastric cancer treatment in the United States and the pursuit of quality. Eur J Surg Oncol. 2005 Aug; 31 (6): 605–15. doi: 10.1016/j.ejso.2005.02.011.

6. Moenig S.P., Luebke T., Baldus S.E., Schroeder W., Bollschweiler E., Schneider P.M., Hoelscher A.H. Feasibility of sentinel node concept in gastric carcinoma: clinicopathological analysis of gastric cancer with solitary lymph node metastasis. Anticancer Res. 2005 Mar-Apr; 25 (2B): 1349–52.

7. Afanasyev S.G., Avgustinovich A.V., Tuzikov S.A., Pak A.V., Volkov M.Yu., Savel’ev I.N., Frolova I.G. Results of combined operations for locally advanced gastric cancer. Onkologija. Zhurnal im. P.A. Gercena. 2013; 2: 12–15. [in Russian]

8. Adachi Y., Shiraishi N., Suematsu T., Shiromizu A., Yamaguchi K., Kitano S. Most important lymph node information: in gastric cancer: multivariate prognostic study. Ann Surg Oncol. 2000 Aug; 7 (7): 503–7.

9. Nashimoto A., Nakajima T., Furukawa H., Kitamura M., Kinoshita T., Yamamura Y., Sasako M., Kunii Y., Motohashi H., Yamamoto S; Gastric Cancer Surgical Study Group, Japan Clinical Oncology Group. Randomized trial of adjuvant chemotherapy with mitomycin, Fluorouracil, and Cytosine arabinoside followed by oral Fluorouracil in serosa-negative gastric cancer: Japan Clinical Oncology Group 9206-1. J Clin Oncol. 2003 Jun 15; 21 (12): 2282–7. doi: 10.1200/JCO.2003.06.103.

10. Roukos D.H., Paraschou P., Lorenz M. Distal gastric cancer and extensive surgery: a new evaluation method based on the study of the status of residual lymph nodes after limited surgery. Ann Surg Oncol. 2000 Dec; 7 (10): 719–26.

11. Davydov М.I., Turkin I.N., Davydov М.М. Encyclopedia of surgery for gastric cancer. М., 2011; 536 p. [in Russian]

12. Turkin I.N., Davydov М.I. What defines the extent of lymphodissection for early gastric cancer. Siberian Journal of Oncology. 2013; 2: 12–17. [in Russian]

13. Karachun А.М., Belyaev А.М., Sinenko G.I., Pelipas Yu.А. Extent of lymph node dissection for gastric cancer (Literature review). Siberian Journal of Oncology. 2011; 5: 70 78. [in Russian]

14. Chissov V.I., Daryalova S.L. Clinical guidelines. Oncology. М. 2009; 213 p. [in Russian]